The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Minimal clinically important change on the unified Parkinson's disease rating scale
Abstract
The Unified Parkinson's Disease Rating Scale (UPDRS) is the main outcome measure in clinical trials of Parkinson's disease (PD). The minimal change that represents a clinically meaningful improvement is unknown. The objective of this study was to determine the minimal change on the UPDRS that represents a clinically meaningful improvement in early PD after 6 months of treatment. Data from two independent randomized treatment trials over 6 months involving 603 patients with de novo PD were analyzed to determine the minimal clinically important change (MCIC), referred to the status before treatment, for the UPDRS motor, activities of daily living (ADL), and total scores. An anchor‐based method using ratings on a seven‐point global clinical improvement was used. A change of five points on the UPDRS motor part was found to be the most appropriate cutoff score for all Hoehn and Yahr stages I to III, and a change of eight points for the UDPRS total score. For the UDPRS ADL score, an MCIC of two points for Hoehn and Yahr stages I/I.5 and II and of three points for Hoehn and Yahr stage II.5/III was the most appropriate cutoff score. These data give the first estimate for cutoffs defining clinically important changes in UPDRS ADL and motor scores. Further studies using larger databases from more diverse study populations are encouraged to better define and solidify the MCIC for the UPDRS. © 2006 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (2003) · Movement Disorders · doi:10.1002/mds.10473 · Cited by 1,810
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Clinical Significance of Reported Changes in Pain Severity☆☆☆★
Todd, K. H., Funk, K. G., Funk, J. P., & Bonacci, R. (1996) · Annals of Emergency Medicine · doi:10.1016/s0196-0644(96)70238-x · Cited by 1,109
Tubach, F., Ravaud, P., Baron, G., Falissard, B., Logeart, I., Bellamy, N., Bombardier, C., Felson, D., Hochberg, M., van der Heijde, D., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.022905 · Cited by 1,094
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up
Rodriguez-Oroz, M. C., Obeso, J. A., Lang, A. E., Houeto, J.-L., Pollak, P., Rehncrona, S., Kulisevsky, J., Albanese, A., Volkmann, J., Hariz, M. I., et al. (2005) · Brain · doi:10.1093/brain/awh571 · Cited by 1,057
Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease
de la Fuente-Fernández, R., Ruth, T. J., Sossi, V., Schulzer, M., Calne, D. B., & Stoessl, A. J. (2001) · Science · doi:10.1126/science.1060937 · Cited by 991
Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease
Lacasse, Y., Wong, E., Guyatt, G. H., King, D., Cook, D. J., & Goldstein, R. S. (1996) · The Lancet · doi:10.1016/s0140-6736(96)04201-8 · Cited by 868
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial
Parkinson Study Group (2000) · JAMA · doi:10.1001/jama.284.15.1931 · Cited by 767
Unified Parkinson’s Disease Rating Scale
Fish, J. (2018) · Encyclopedia of Clinical Neuropsychology · doi:10.1007/978-3-319-57111-9_1836 · Cited by 403
Shannon, K. M., Bennett, J. P., Friedman, J. H., & the Pramipexole Study Group (1997) · Neurology · doi:10.1212/wnl.49.3.724 · Cited by 281
Ropinirole for the treatment of early Parkinson's disease
Adler, C. H., Sethi, K. D., Hauser, R. A., Davis, T. L., Hammerstad, J. P., Bertoni, J., Taylor, R. L., Sanchez-Ramos, J., O'Brien, C. F., & Ropinirole Study Group (1997) · Neurology · doi:10.1212/wnl.49.2.393 · Cited by 281
Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire
Peto, V. (2001) · Age and Ageing · doi:10.1093/ageing/30.4.299 · Cited by 227
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease
Lieberman, A., Olanow, C. W., Sethi, K., Swanson, P., Waters, C. H., Fahn, S., Hurtig, H., Yahr, M., & the Ropinirole Study Group* (1998) · Neurology · doi:10.1212/wnl.51.4.1057 · Cited by 223
Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study
Oertel, W. H., Wolters, E., Sampaio, C., Gimenez‐Roldan, S., Bergamasco, B., Dujardin, M., Grosset, D. G., Arnold, G., Leenders, K. L., Hundemer, H., et al. (2006) · Movement Disorders · doi:10.1002/mds.20724 · Cited by 210
Self-citationGuttman, M., & International Pramipexole-Bromocriptine Study Group (1997) · Neurology · doi:10.1212/wnl.49.4.1060 · Cited by 209
Clinically important change in quality of life in epilepsy
Wiebe, S. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.2.116 · Cited by 187
Rascol, O., Brooks, D. J., Brunt, E. R., Korczyn, A. D., Poewe, W. H., & Stocchi, F. (1998) · Movement Disorders · doi:10.1002/mds.870130111 · Cited by 186
Self-citationBrooks, D. J. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.8.1071 · Cited by 182
A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease
Korczyn, A. D., Brunt, E. R., Larsen, J. O., Nagy, Z., Poewe, W. H., & Ruggieri, S. A. (1999) · Neurology · doi:10.1212/wnl.53.2.364 · Cited by 142
Self-citationKorczyn, A. D., Brooks, D. J., Brunt, E. R., Poewe, W. H., Rascol, O., & Stocchi, F. (1998) · Movement Disorders · doi:10.1002/mds.870130112 · Cited by 130
Self-citationStern, M. B., MAREK, K. L., Friedman, J. H., Hauser, R. A., LeWitt, P. A., Tarsy, D., & Olanow, C. W. (2004) · Movement Disorders · doi:10.1002/mds.20145 · Cited by 118
Pergolide monotherapy in the treatment of early PD
Barone, P., Bravi, D., Bermejo‐Pareja, F., Marconi, R., Kulisevsky, J., Malagù, S., Weiser, R., Rost, N. S., & the Pergolide Monotherapy Study Group (1999) · Neurology · doi:10.1212/wnl.53.3.573 · Cited by 102
Key Methodological Features of Randomized Controlled Trials of Alzheimer’s Disease Therapy
Burback, D., Molnar, F., John, P. S., & Man‐Son‐Hing, M. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017201 · Cited by 102
Lepola, U. M., Wade, A. G., & Andersen, H. F. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200405000-00005 · Cited by 91
Brunt, E. R., Brooks, D. J., Korczyn, A. D., Montastruc, J., & Stocchi, F. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200040 · Cited by 66
Jaggi, J. L., Jaggi, J. L., Umemura, A., Umemura, A., Hurtig, H. I., Hurtig, H. I., Siderowf, A. D., Siderowf, A. D., Colcher, A., Colcher, A., et al. (2004) · Stereotactic and Functional Neurosurgery · doi:10.1159/000078145 · Cited by 66
Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder
McRae‐Clark, A. L., Brady, K. T., Mellman, T. A., Sonne, S. C., Killeen, T. K., Timmerman, M. A., & Bayles-Dazet, W. (2004) · Depression and Anxiety · doi:10.1002/da.20008 · Cited by 60
Ziegler, M., Castro‐Caldas, A., Signore, S. D., & Rascol, O. (2003) · Movement Disorders · doi:10.1002/mds.10359 · Cited by 60
Cited by
Weaver, F. M. (2009) · JAMA · doi:10.1001/jama.2008.929 · Cited by 1,525
Pallidal versus Subthalamic Deep-Brain Stimulation for Parkinson's Disease
Follett, K. A., Weaver, F. M., Stern, M., Hur, K., Harris, C. L., Luo, P., Marks, W. J., Rothlind, J., Sagher, O., Moy, C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907083 · Cited by 1,355
Williams, A., Gill, S., Varma, T., Jenkinson, C., Quinn, N., Mitchell, R., Scott, R., Ives, N., Rick, C., Daniels, J., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70093-4 · Cited by 733
van der Kolk, N. M., de Vries, N. M., Kessels, R. P. C., Joosten, H., Zwinderman, A. H., Post, B., & Bloem, B. R. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30285-6 · Cited by 565
The Clinically Important Difference on the Unified Parkinson's Disease Rating Scale
Shulman, L. M., Gruber-Baldini, A. L., Anderson, K. E., Fishman, P. S., Reich, S. G., & Weiner, W. J. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.295 · Cited by 494
Metadata
- Authors
- Schrag, A., Sampaio, C., Counsell, N., & Poewe, W.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2006-05-03
- Volume
- 21
- Issue
- 8
- Pages
- 1200-1207
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2103304172
- Cited by
- 297
- References
- 32
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.